GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Huawei Launches Mate XT2 Foldable Phone in China 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Milei Threatens Falkland Oil Firms With Sanctions 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Spire Healthcare Shares Jump on £1.03 Billion Takeover Deal 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Ingenia Rejects A$1.9 Billion Warburg Pincus Takeover Bid 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
Add as a preferred source on Google
Swiss pharmaceutical giant Novartis (SIX:NOVN) has reaffirmed its commitment to producing life-saving treatments for malaria and leprosy, even amid uncertainty over global health funding. According to Dr. Lutz Hegemann, President of Global Health at Novartis, the company will continue manufacturing its 28 million annual malaria treatment courses regardless of demand or funding disruptions.
Most of Novartis' antimalarial drugs are sold at a not-for-profit price to global initiatives, including the U.S.-funded President’s Malaria Initiative (PMI). However, recent aid cuts under President Donald Trump have threatened such programs. Earlier this year, a contractor for PMI canceled an order due to a government stop-work directive, but resumed the request shortly after receiving an exemption. “We are not going to be the bottleneck,” said Hegemann, emphasizing the company's commitment to maintaining supply even during funding gaps.
The Global Fund to Fight AIDS, Tuberculosis and Malaria remains the largest purchaser of Novartis' malaria treatments. While it has not yet faced funding cuts, it is actively seeking donations in a difficult financial environment.
Speaking from London, Hegemann urged the pharmaceutical industry to take a more proactive role in global health, advocating for deeper collaborations with low- and middle-income countries. He stressed that companies should go beyond merely compensating for shrinking donor aid and instead foster long-term public-private partnerships.
Novartis is also ramping up its R&D spending on malaria and neglected tropical diseases. The company expects to invest $490 million by 2025—nearly double its original $250 million pledge. Ongoing projects include a dengue antiviral, new therapies for leishmaniasis and Chagas disease, and the first malaria drug designed for newborns.
This strong commitment highlights Novartis’ leadership in global health and its resolve to support vulnerable communities worldwide.
